deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00985192

Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach

Sponsor: National Cancer Institute (NCI)

Updated 9 times since 2017 Last updated: Aug 3, 2020 Started: Sep 30, 2009 Primary completion: May 31, 2014 Completion: May 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Esophageal Cancer and Gastric Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 9 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Mar 2020 · 21 months · monthly snapshotCompleted~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

Show 4 earlier versions
  1. Mar 2020 — Sep 2020 [monthly]

    Completed PHASE2

  2. Jun 2018 — Mar 2020 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Translational Oncology Research International
  • University of California, Los Angeles
Data source: Translational Oncology Research International

For direct contact, visit the study record on ClinicalTrials.gov .